Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer

Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. The benefit reported in this trial appeared later in follow up of the women in the study. —> Read More